The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

How to navigate early clinical development and support robust registrational strategy and late-stage development in oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The clinical development strategy in oncology during the last decade has been substantially affected in several ways by the advent of immunotherapy1, and more recently, cell and gene therapy2 treatment options. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Tanja Obradovic, PhD
Vice president, Scientific Affairs, Medical Affairs Oncology, ICON Biotech
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Nivolumab + epigenetic drug induce immune response in some resistant pancreatic cancers

In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor. 
Clinical Roundup

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.
Byline
Tanja Obradovic, PhD
Vice president, Scientific Affairs, Medical Affairs Oncology, ICON Biotech
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account